Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02974725
Title	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Recruitment	Terminated
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	melanoma lung non-small cell carcinoma
Therapies	LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254
Age Groups:	adult \| senior
Covered Countries	USA \| SWE \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| BEL \| AUS